Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) was downgraded by analysts at Piper Jaffray Cos. from an “overweight” rating to a “neutral” rating in a report issued on Tuesday.

A number of other equities analysts have also issued reports on VTAE. Wedbush reissued an “outperform” rating and set a $23.00 price target on shares of Vitae Pharmaceuticals in a report on Wednesday, May 25th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Vitae Pharmaceuticals in a report on Friday, June 10th. Zacks Investment Research lowered Vitae Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 13th. JMP Securities lowered Vitae Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, August 4th. Finally, Stifel Nicolaus lowered Vitae Pharmaceuticals from a “buy” rating to a “hold” rating and set a $21.00 price objective on the stock. in a report on Wednesday, September 14th. Seven research analysts have rated the stock with a hold rating, The company presently has a consensus rating of “Hold” and a consensus price target of $19.05.

Analyst Recommendations for Vitae Pharmaceuticals (NASDAQ:VTAE)

Vitae Pharmaceuticals (NASDAQ:VTAE) traded up 0.14% during midday trading on Tuesday, hitting $20.88. The stock had a trading volume of 877,558 shares. Vitae Pharmaceuticals has a 12-month low of $4.08 and a 12-month high of $20.97. The stock has a 50-day moving average price of $9.66 and a 200 day moving average price of $8.73. The firm’s market cap is $602.20 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/vitae-pharmaceuticals-inc-vtae-lowered-to-neutral-at-piper-jaffray-cos.html

Vitae Pharmaceuticals (NASDAQ:VTAE) last released its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.05. Vitae Pharmaceuticals had a negative return on equity of 65.51% and a negative net margin of 13,954.35%. During the same quarter last year, the company earned ($0.45) EPS. The business’s quarterly revenue was down 98.0% on a year-over-year basis. On average, equities analysts anticipate that Vitae Pharmaceuticals will post ($1.64) earnings per share for the current fiscal year.

In other news, CEO Jeffrey S. Hatfield sold 50,000 shares of Vitae Pharmaceuticals stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $20.81, for a total transaction of $1,040,500.00. Following the completion of the sale, the chief executive officer now directly owns 244,996 shares in the company, valued at approximately $5,098,366.76. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Adage Capital Partners Gp, L.L sold 1,025,000 shares of Vitae Pharmaceuticals stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $20.85, for a total transaction of $21,371,250.00. The disclosure for this sale can be found here. Insiders own 14.80% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. FMR LLC increased its stake in Vitae Pharmaceuticals by 65.4% in the second quarter. FMR LLC now owns 4,179,473 shares of the company’s stock worth $45,097,000 after buying an additional 1,653,200 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in Vitae Pharmaceuticals by 58.1% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,400,000 shares of the company’s stock worth $22,542,000 after buying an additional 1,250,000 shares during the last quarter. Cormorant Asset Management LLC increased its stake in Vitae Pharmaceuticals by 178.3% in the first quarter. Cormorant Asset Management LLC now owns 1,735,000 shares of the company’s stock worth $11,503,000 after buying an additional 1,111,591 shares during the last quarter. BlackRock Fund Advisors increased its stake in Vitae Pharmaceuticals by 66.5% in the second quarter. BlackRock Fund Advisors now owns 1,050,353 shares of the company’s stock worth $11,333,000 after buying an additional 419,667 shares during the last quarter. Finally, Mitra Capital LLC bought a new stake in Vitae Pharmaceuticals during the first quarter worth about $2,671,000. Institutional investors own 72.93% of the company’s stock.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.

5 Day Chart for NASDAQ:VTAE

Receive News & Ratings for Vitae Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.